Marc Schermerhorn: Mortality analysis of EVAS vs. EVAR


Marc Schermerhorn (Boston, USA) discusses the three-year results of an analysis on the long-term survival of Nellix EVAS system (Endologix) IDE trial patients vs. a cohort of EVAR patients. The study found that EVAS is associated with higher long-term survival, with a 41% difference in overall mortality rates between the two cohorts—a number that increases to 50% for patients with >5.5cm aneurysm diameters.

(Visited 306 times, 10 visits today)


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.